株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

2型糖尿病:パイプライン製品の分析

Type 2 Diabetes - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 232774
出版日 ページ情報 英文 1109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.57円で換算しております。
Back to Top
2型糖尿病:パイプライン製品の分析 Type 2 Diabetes - Pipeline Review, H1 2018
出版日: 2018年05月31日 ページ情報: 英文 1109 Pages
概要

2型糖尿病は慢性的な症状で、最もよく見られる糖尿病です。血糖値が高いのが特徴で、体がインスリンに対して抵抗したり、十分なインスリンを生成することができなくなります。インスリン機能の異常によってグルコースが濃縮されて血糖値が高くなり、2型糖尿病を引き起こします。症候は、疲労感、体重の減少、目のかすみなどの様々な影響が出てきます。リスク要因として、家族の病歴、連例、肥満、運動不足、高血圧などが挙げられます。ライフスタイルの見直しや、定期的な薬物治療などで対処します。

当レポートでは、2型糖尿病の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

2型糖尿病の概要

治療薬の開発

2型糖尿病:治療薬の評価

2型糖尿病の治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

目次
Product Code: GMDHC10467IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2018, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type2 diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 29, 63, 72, 6, 220, 65 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 18 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 11
  • Type2 diabetes - Overview 12
  • Type2 diabetes - Therapeutics Development 13
  • Type2 diabetes - Therapeutics Assessment 67
  • Type2 diabetes - Companies Involved in Therapeutics Development 88
  • Type2 diabetes - Drug Profiles 177
  • Type2 diabetes - Dormant Projects 996
  • Type2 diabetes - Discontinued Products 1035
  • Type2 diabetes - Product Development Milestones 1045
  • Appendix 1055

List of Tables

  • Number of Products under Development for Type2 diabetes, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Type2 diabetes - Pipeline by Adocia SAS, H1 2018
  • Type2 diabetes - Pipeline by Aegis Therapeutics LLC, H1 2018
  • Type2 diabetes - Pipeline by AFFiRiS AG, H1 2018
  • Type2 diabetes - Pipeline by Akcea Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018
  • Type2 diabetes - Pipeline by Amgen Inc, H1 2018
  • Type2 diabetes - Pipeline by Aphios Corp, H1 2018
  • Type2 diabetes - Pipeline by Arecor Ltd, H1 2018
  • Type2 diabetes - Pipeline by Arena Pharmaceuticals Inc, H1 2018
  • Type2 diabetes - Pipeline by AstraZeneca Plc, H1 2018
  • Type2 diabetes - Pipeline by AusBio Ltd, H1 2018
  • Type2 diabetes - Pipeline by Avadel Pharmaceuticals Plc, H1 2018
  • Type2 diabetes - Pipeline by Bayer AG, H1 2018
  • Type2 diabetes - Pipeline by Betagenon AB, H1 2018
  • Type2 diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Biocon Ltd, H1 2018
  • Type2 diabetes - Pipeline by BioLingus AG, H1 2018
  • Type2 diabetes - Pipeline by BioRestorative Therapies Inc, H1 2018
  • Type2 diabetes - Pipeline by Biozeus, H1 2018
  • Type2 diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018
  • Type2 diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Type2 diabetes - Pipeline by Boston Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Braasch Biotech LLC, H1 2018
  • Type2 diabetes - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Type2 diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2018
  • Type2 diabetes - Pipeline by Cadila Healthcare Ltd, H1 2018
  • Type2 diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H1 2018
  • Type2 diabetes - Pipeline by Caelus Health, H1 2018
  • Type2 diabetes - Pipeline by Cardax Inc, H1 2018
  • Type2 diabetes - Pipeline by Carmot Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Cellix Bio Pvt Ltd, H1 2018
  • Type2 diabetes - Pipeline by Celon Pharma SA, H1 2018
  • Type2 diabetes - Pipeline by Center Laboratories Inc, H1 2018
  • Type2 diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2018
  • Type2 diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
  • Type2 diabetes - Pipeline by Cinnagen Co, H1 2018
  • Type2 diabetes - Pipeline by CJ HealthCare Corp, H1 2018
  • Type2 diabetes - Pipeline by CohBar Inc, H1 2018
  • Type2 diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H1 2018
  • Type2 diabetes - Pipeline by CymaBay Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Dance Biopharm Inc, H1 2018
  • Type2 diabetes - Pipeline by Delpor Inc, H1 2018
  • Type2 diabetes - Pipeline by Diabetology (Products) Ltd, H1 2018
  • Type2 diabetes - Pipeline by Diamyd Medical AB, H1 2018
  • Type2 diabetes - Pipeline by Diasome Pharmaceuticals Inc, H1 2018
  • Type2 diabetes - Pipeline by DiscoveryBiomed Inc, H1 2018
  • Type2 diabetes - Pipeline by DNJ Pharma Inc, H1 2018
  • Type2 diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Elcelyx Therapeutics Inc, H1 2018
  • Type2 diabetes - Pipeline by Eli Lilly and Co, H1 2018
  • Type2 diabetes - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018
  • Type2 diabetes - Pipeline by Energenesis Biomedical Co Ltd, H1 2018
  • Type2 diabetes - Pipeline by Enteris BioPharma Inc, H1 2018
  • Type2 diabetes - Pipeline by Enzene Biosciences Ltd, H1 2018
  • Type2 diabetes - Pipeline by Enzo Biochem Inc, H1 2018
  • Type2 diabetes - Pipeline by Epichem Pty Ltd, H1 2018
  • Type2 diabetes - Pipeline by Eternygen GmbH, H1 2018
  • Type2 diabetes - Pipeline by Evotec AG, H1 2018

List of Figures

  • Number of Products under Development for Type2 diabetes, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top